Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of ONO-7057 (carfilzomib) plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma
jRCT2080222626Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2014
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by Ono Pharmaceutical. Primary endpoints: Safety and tolerability of CRd regimen and Pharmacokinetics of ONO-7057. Started Oct 2014; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080222626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222626.